<?xml version="1.0" encoding="UTF-8"?>
<results title="funders">
 <result pre="America[3], Department of Molecular Microbiology &amp;amp; Immunology, Saint Louis University" exact="School of Medicine," post="Saint Louis, Missouri, United States of America[4], Host Pathogen"/>
 <result pre="Biomedical Research Institute, San Antonio, Texas, United States of America[5]," exact="University of North Carolina" post="Chapel Hill, North Carolina, United States of America[6], Department"/>
 <result pre="Puerto Rico, United States of AmericaSamyAbdallah M.Editor[], Faculty of Science," exact="Ain Shams University" post="(ASU), EGYPT The authors have declared that no competing"/>
 <result pre="grant P51 OD011133 from the Office of Research Infrastructure Programs," exact="National Institutes of Health" post="to LDG. The funders had no role in study"/>
 <result pre="= 0.042 vs. naïve and P = 0.019 vs. DENV" exact="3M" post="group). By day 5 p.i. all three groups had"/>
 <result pre="viral RNA detection in the DENV-middle convalescent group, while DENV" exact="3M" post="animals showed a trend towards an intermittent viremia and"/>
 <result pre="measured using qRT-PCR, but only one animal from the DENV" exact="3M" post="group (MA023) had detectable levels at day 6 p.i."/>
 <result pre="mean diff: -0.3, CI95% -0.4997 to -0.1003 for the DENV" exact="3M" post="and DENV 12M groups respectively). Those cross-reacting Abs were"/>
 <result pre="P&amp;lt;0.0001; mean diff.: 0.75, CI95%: 0.37 to 1.14 for DENV" exact="3M" post="vs naïve at 30 days p.i.; P&amp;lt;0.0001; mean diff.:"/>
 <result pre="P&amp;lt;0.001; mean diff.: 0.68, CI95%: 0.29 to 1.07 for DENV" exact="3M" post="vs naïve at 60 days p.i.), slowly decreasing by"/>
 <result pre="P&amp;lt;0.0001; mean diff.: -1.176, CI95%: -1.716 to -0.636 for DENV" exact="3M" post="and DENV 12M groups respectively (S4D Fig). The same"/>
 <result pre="P&amp;lt;0.001; mean diff.: -1.26, CI95%: -2.27 to -0.25 for DENV" exact="3M" post="animals). No significant differences were observed among the groups,"/>
 <result pre="levels of dilution effective for half-maximum neutralization compared to DENV" exact="3M" post="and naïve groups. These levels decline slightly by day"/>
 <result pre="day 6 (P&amp;lt;0.001 and P&amp;lt;0.029 for DENV 12M and DENV" exact="3M" post="vs. naïve respectively at 1:20 dilution and P ="/>
 <result pre="P = 0.0005 and P&amp;lt;0.0001 for DENV 12M vs. DENV" exact="3M" post="and naïve respectively at 1:40 dilution) and day 7"/>
 <result pre="envelopes and ZIKV non-structural proteins as well compared to the" exact="3M" post="and naïve groups. Fig 5 Antigen-specific CD4+ and CD8+"/>
 <result pre="12M animals had seemingly higher levels compared to their DENV" exact="3M" post="counterparts, although no statistical significance was reached. From days"/>
 <result pre="(P&amp;lt;0.05; mean diff.: -12.33, CI95%: -22.69 to -1.979 for DENV" exact="3M" post="versus DENV 12M, and P&amp;lt;0.01; mean diff.: 14.77, CI95%:"/>
 <result pre="P&amp;lt;0.01; mean diff.: 14.77, CI95%: 4.41 to 25.12 for DENV" exact="3M" post="versus naïve group). No other differences between groups were"/>
 <result pre="2 p.i. in DENV 12M animals in comparison with DENV" exact="3M" post="and naïve animals (P&amp;lt;0.01; mean diff.: 10.54, CI95%: -2.65"/>
 <result pre="13.68, CI95%: 4.87 to 22.50 for DENV 12M versus DENV" exact="3M" post="and, P&amp;lt;0.0001; mean diff.: 15.57, CI95%: 7.68 to 23.45"/>
 <result pre="isolated from the 12M DENV immune animals compared to the" exact="3M" post="DENV immune animals. Our finding on CD4+ T cells"/>
 <result pre="levels of pDC frequency in comparison with animals from DENV" exact="3M" post="and naïve groups and with its own baseline levels."/>
 <result pre="the protocol developed by the Molecular Diagnostics and Research Laboratory" exact="Centers for Disease Control and Prevention" post="(CDC), Dengue Branch at San Juan, PR. RNA from"/>
 <result pre="Severe Thrombocytopenia. Clinical infectious diseases: an official publication of the" exact="Infectious Diseases Society of America." post="2016; Epub 2016/07/16. 10.1093/cid/ciw476 .27418575 9D’OrtenzioE, MatheronS, YazdanpanahY, de"/>
 <result pre="January-April 2016. Clinical infectious diseases: an official publication of the" exact="Infectious Diseases Society of America." post="2017;64(2):211–3. Epub 2016/12/18. 10.1093/cid/ciw692 .27986688 12CostaF, SarnoM, KhouriR, de"/>
 <result pre="Dengue Virus. Clinical infectious diseases: an official publication of the" exact="Infectious Diseases Society of America." post="2016;63(12):1584–90. Epub 2016/09/01. 10.1093/cid/ciw589 .27578819 42AliotaMT, DudleyDM, NewmanCM, MohrEL,"/>
 <result pre="Zika Patients. Clinical infectious diseases: an official publication of the" exact="Infectious Diseases Society of America." post="2018;66(1):1–10. Epub 2017/10/12. 10.1093/cid/cix732 .29020226 52PatelB, LongoP, MileyMJ, MontoyaM,"/>
 <result pre="dengue virus NS3 are associated with DHF. Proceedings of the" exact="National Academy of Sciences" post="of the United States of America. 2010;107(39):16922–7. Epub 2010/09/15."/>
 <result pre="CD4+ T cells associated with protective immunity. Proceedings of the" exact="National Academy of Sciences" post="of the United States of America. 2015;112(31):E4256–63. Epub 2015/07/22."/>
</results>
